Preclinical pharmacokinetics of CASC-578, a novel, selective, potent, and orally bioavailable small molecule checkpoint kinase 1 inhibitor
Previous
Previous
Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS
Next
Next